ability to block PD-1:PD-L1 interactions has altered our approach to the management of many solid malignancies including head and neck cancer. Despite the success of these therapies ... management of head and neck…
been reported also following checkpoint inhibitor treatment. We compared CD3+, CD4+, CD8+, CD20+, CD56+, PD-1+ and PD-L1+ lymphocyte infiltrates in liver biopsies of patients that encountered VBDS ... inhibitor-treated…
Background: Immune-related skin rash is common in patients receiving PD-1/PD-L1-based immune checkpoint inhibitor therapy. This study aimed to explore whether development of rash is predicative ... outcomes in patients…
patient with this disease. Two decades of studies have investigated the prognostic value of PD-1/PD-L1 in high-grade serous ovarian carcinoma; many issues remain unclear, controversial, inconsistent ... often…
Background: PD-L1 is expressed widely in the body. PD-1-PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD ... antibodies. Researchers have shown that blocking PD-L1 in both the…
adverse reactions caused by using programmed cell death-1/programmed cell death ligand-1(PD-1/PD-L1) inhibitors were evaluated. PD-1 is an immune checkpoint receptor which expresses ... activates specific immune cells…
PD-L1 articulation in tumour tissues is broadly used to choose patients to get hostile to PD-1/PD-L1 antibodies, yet information is missing on the relationship of plasma ... PD-L1 levels with the impact of treatments…
progress of computational imaging analysis and radiomics-based biomarkers for evaluating efficacy of anti-PD-1/PD-L1 immunotherapy, and predicting immunerelated side effects
Generalized anxiety disorder (GAD) and panic disorder (PD) are among the most common mental disorders in the United States, and they can negatively impact a patient's quality of life ... living. Evidence suggests that…
symptoms and poor responsiveness to dopaminergic drugs. He has been diagnosed as Parkinson disease (PD) at the baseline and Parkinson Disease Dementia (PDD) at last. The patient’s post-mortem ... study did not conform…
palladium catalysts is still a challenge. Not only complexes but also palladium nanoparticles (Pd NPs) should be taken into account [5-6]. In our studies, Pd/DNA catalysts were prepared ... mixed H2O/EtOH solvent using…
corresponding complexes of these ligand were synthesized by the reaction of the ligand with Pd(II), Pt(II) at molar ratio of 1:2. The structures of complexes were identified ... parent cationic species [M]+. This…
Pd-catalyzed decarboxylation and dual C(sp3)-H bond functionalization approaches have been described for the preparation of symmetrical and unsymmetrical 2,4-diarylpyridines. The developed transformations were realized…
desorption of CO from Pd (111) induced by femtosecond laser pulses is probed by IR + vis sum frequency generation (SFG). A large redshift of the main band, a broadening ... electron and phonon heat baths within the…
onset and is currently the only immunological biomarker of disease progression. Programmed death-1 (PD-1) is a T cell inhibitory receptor, and it is highly expressed on recently activated ... exhausted) CD8+ T cells…
interaction of PD-L1 with T cell PD-1 receptor leads to the inactivation and death of T cells resulting in immunosuppression and undisturbed tumor development. We engineered Salmonella strain ... deliver soluble PD-1…
synthase 2 (HAS2)-CD44 cancer stemness pathway and upregulation of the immune checkpoint regulator PD-L1 upon TGIF1 loss in PDAC facilitate the epithelialmesenchymal transition (EMT) and tumor immune suppression
cell or B-cell lymphoma with anaplastic features and/or CD30 expression. PD-L1/PD-1 check point physiologically plays a key role in induction and maintenance of immune tolerance ... self-antigens and limits normal…
then, several drugs and clinical trials have been designed that either block the receptor PD-1 or its ligand PD-L1. Recent approval of four different PD-1/PD ... inhibitor drugs avelumab, pembrolizumab, nivolumab and…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.